When a unit of insulin is not a unit: Detemir dosing and insulin cost in type 2 diabetes mellitus

Insulin

Volumn 4, Issue 2, 2009, Pages 87-93

  Johnson, Christopher K ^a   Shimshi, Mona ^b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

aspart; cost; detemir; equivalence; glargine; NPH insulin; type 2 diabetes

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ARTICLE; BODY WEIGHT; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; EVENING DOSAGE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MEDLINE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 65349162840     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(09)80017-1     Document Type: Article

References (30)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 27 (2004) 1047-1053
2. Bays H.E., Chapman R.H., Grandy S., and the SHIELD Investigators' Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: Comparison of data from two national surveys [published correction appears in Int J Clin Pract. 2007;61:1777-1778]. Int J Clin Pract. 61 (2007) 737-747
3. Narayan K.M., Boyle J.P., Thompson T.J., et al. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 30 (2007) 1562-1566
4. Wright A., Burden A.C., Paisey R.B., et al., the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) [published correction appears in Diabetes Care. 2002;25:1268]. Diabetes Care. 25 (2002) 330-336
5. Ihnat M.A., Thorpe J.E., and Ceriello A. Hypothesis: The 'metabolic memory', the new challenge of diabetes. Diabet Med. 24 (2007) 582-586
6. Kahn S.E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 86 (2001) 4047-4058
7. Levy J., Atkinson A.B., Bell P.M., et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study. Diabet Med. 15 (1998) 290-296
8. Meece J. Pharmacoeconomic advantages of insulin analogs. US Pharm. 31 (2006) HS42-HS50
9. Zammitt N.N., and Frier B.M. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 28 (2005) 2948-2961
10. Polonsky W.H., and Jackson R.A. What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes. 22 (2004) 147-150
11. Lee W.C., Balu S., Cobden D., et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data [published correction appears in Clin Ther. 2006;28:1968-1969]. Clin Ther. 28 (2006) 1712-1725 discussion
12. Lee W.C., Balu S., Cobden D., et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data [published correction appears in Clin Ther. 2006;28:1968-1969]. Clin Ther. 28 (2006) 1710-1711
13. Leese G.P., Wang J., Broomhall J., et al., the DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care. 26 (2003) 1176-1180
14. Tran K., Banerjee S., Li H., et al. Long-acting insulin analogues for diabetes mellitus: Meta-analysis of clinical outcomes and assessment of cost-effectiveness [Technology Report number 92] (2007), Canadian Agency for Drugs and Technologies in Health, Ottawa
15. Hirsch I.B. Insulin analogues. N Engl J Med. 352 (2005) 174-183
16. Mahoney J.J. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 11 Suppl 5 (2005) S170-S176
17. Warren E., Weatherley-Jones E., Chilcott J., and Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 8 iii (2004) 1-57
18. Siebenhofer A., Plank J., Berghold A., et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. (2006) CD003287
19. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypo-glycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 28 (2005) 950-955
20. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [published correction appears in Diabetes Care. 2007;30:1035]. Diabetes Care. 29 (2006) 1269-1274
21. Drugstore.com. http://www.drugstore.com Accessed December 8, 2008
22. Raslová K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes [published correction appears in Diabetes Res Clin Pract. 2006;72:112]. Diabetes Res Clin Pract. 66 (2004) 193-201
23. Haak T., Tiengo A., Draeger E., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 7 (2005) 56-64
24. Liebl A., Prager R., Binz K., et al., the PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: A randomized controlled trial. Diabetes Obes Metab. 11 (2009) 45-52
25. Rosenstock J., Davies M., Home P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 51 (2008) 408-416
26. Philis-Tsimikas A., Charpentier G., Clauson P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes [published correction appears in Clin Ther. 2006;28:1967]. Clin Ther. 28 (2006) 1569-1581
27. Umpierrez G.E., Hor T., Smiley D., et al. Comparison of inpatient insulin regimens with detemir plus aspart versus NPH plus regular in medical patients with type 2 diabetes. J Clin Endocrin Metab. 94 (2009) 564-569
28. Misbin R.I. Medical Officer Review NDA 21536 (2005), US Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC
29. Vague P., Selam J.L., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 26 (2003) 590-596
30. Poole C.D., Tetlow T., McEwan P., et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: A retrospective database analysis. Curr Med Res Opin. 23 Suppl (2007) S41-S48